Clinical Trial Update: An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder [Phase 4]

View source ↗

Summary

This Phase 4 open-label extension evaluated lamotrigine in bipolar disorder. The study has completed and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Lamotrigine (lamotrigine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Bipolar Disorder | Phase 4 | Status: COMPLETED | Results posted: 2017-03-30